Healthcare Intelligence
Dermatology Industry
Real-time intelligence, expert analysis, and verified research for the Dermatology Industry industry. Stay ahead in 3 minutes a day.
Stay ahead of Dermatology Industry in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Povorcitinib Shows 1-Year Vitiligo Repigmentation in Phase 3 Trials
Incyte's oral JAK1 inhibitor achieved primary endpoints in STOP-V1 and STOP-V2 trials, with 18.9% achieving 75% facial repigmentation vs 6.8% placebo.
Read full articleDermata Therapeutics Pivots to DTC Skincare, Launches Tome Brand
Company shifts from pharma to consumer skincare, planning mid-2026 launch of once-weekly Foundational Treatment for skin renewal.
Read full articleFDA Expands Dupixent Approval for Chronic Urticaria in Children 2-11
Dupixent receives FDA approval for chronic spontaneous urticaria in young children who remain symptomatic despite antihistamine treatment.
Read full articleOpzelura Shows Sustained 24-Week Efficacy in Moderate Atopic Dermatitis
Incyte's TRuE-AD4 trial shows 84.3% of patients maintained EASI75 response at Week 24, supporting EU regulatory application.
Read full articleTRuE-AD4 Trial: Opzelura Maintains Disease Control Through 24 Weeks
Phase 3 data shows durable symptom control with 70.6% achieving IGA-TS at Week 24, no new safety signals identified.
Read full articleIncyte Q1 2026: Positive Povorcitinib Data Drives Financial Success
CEO highlights positive registrational data for povorcitinib in vitiligo as key Q1 achievement, regulatory filings planned for early 2027.
Read full articleDermata Raises $2M, Extends Cash Runway to Q1 2027
Company secures funding through ATM offering to support DTC skincare pivot and upcoming Tome product launches.
Read full articleOpzelura EU Expansion: Type-II Variation Submitted for Moderate AD
Incyte seeks European approval for ruxolitinib cream in moderate atopic dermatitis, regulatory feedback expected in first half of 2026.
Read full articlePovorcitinib Shows 1-Year Vitiligo Repigmentation in Phase 3 Trials
Incyte's oral JAK1 inhibitor achieved primary endpoints in STOP-V1 and STOP-V2 trials, with 18.9% achieving 75% facial repigmentation vs 6.8% placebo.
Read full articleDermata Therapeutics Pivots to DTC Skincare, Launches Tome Brand
Company shifts from pharma to consumer skincare, planning mid-2026 launch of once-weekly Foundational Treatment for skin renewal.
Read full articleFDA Expands Dupixent Approval for Chronic Urticaria in Children 2-11
Dupixent receives FDA approval for chronic spontaneous urticaria in young children who remain symptomatic despite antihistamine treatment.
Read full articleOpzelura Shows Sustained 24-Week Efficacy in Moderate Atopic Dermatitis
Incyte's TRuE-AD4 trial shows 84.3% of patients maintained EASI75 response at Week 24, supporting EU regulatory application.
Read full articleTRuE-AD4 Trial: Opzelura Maintains Disease Control Through 24 Weeks
Phase 3 data shows durable symptom control with 70.6% achieving IGA-TS at Week 24, no new safety signals identified.
Read full articleIncyte Q1 2026: Positive Povorcitinib Data Drives Financial Success
CEO highlights positive registrational data for povorcitinib in vitiligo as key Q1 achievement, regulatory filings planned for early 2027.
Read full articleDermata Raises $2M, Extends Cash Runway to Q1 2027
Company secures funding through ATM offering to support DTC skincare pivot and upcoming Tome product launches.
Read full articleOpzelura EU Expansion: Type-II Variation Submitted for Moderate AD
Incyte seeks European approval for ruxolitinib cream in moderate atopic dermatitis, regulatory feedback expected in first half of 2026.
Read full articleStay ahead of Dermatology Industry in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.